Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Reveals First Doctor Payments amid Delays in Disclosure
August 19, 2014
- Eisai Licenses Pariet Successor to Zeria
August 19, 2014
- Eisai Files for Regulatory Approval of Lenvatinib in US, Europe
August 19, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
August 18, 2014
- Genzyme Japan Appoints Former Bausch & Lomb Japan President Ashikaga as Its New President
August 18, 2014
- Teva Receives Marketing Authorization for 4 APIs/9 Products
August 18, 2014
- Santen Files NDA for Cosopt Mini for Glaucoma and Ocular Hypertension
August 18, 2014
- GSK Seeks Japan Regulatory Approval for Colistin
August 14, 2014
- Ethical Drug Sales Edge 0.4% Higher in June: Crecon Report
August 14, 2014
- Matsumotokiyoshi Holdings to Transfer OTC Drug-Related Wholesale Business to Alfresa Healthcare
August 14, 2014
- Japan Pharma Market Loses Ground in April-June, Nexium Joins Top 10 List: IMS
August 12, 2014
- PIII Study of Halaven for Advanced NSCLC Fails to Improve OS: Eisai
August 12, 2014
- US FDA Approves Velcade Retreatment in Patients with Multiple Myeloma: Takeda
August 12, 2014
- Astellas Ties Up with Cancer Research UK for Joint Research for Cancer Treatments
August 12, 2014
- Asahi Kasei Pharma Aims to Achieve Sales Target of 100 Billion Yen in FY2015 Despite Debut of Flivas Generics: President
August 11, 2014
- University of Tokyo, Fujitsu, Kowa Discover Novel Anticancer Drug Candidate through IT-Based Drug Discovery Technology
August 11, 2014
- Kowa Files Livalo for Pediatric Indication
August 11, 2014
- Sanofi Files NDA for Hydroxychloroquine
August 11, 2014
- Sumitomo Dainippon Reexamining Midterm Plan Due to Halt of BBI608 Study
August 8, 2014
- JPWA Members Still on Recovery Track with 0.88% Operating Margin in FY2013
August 8, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…